Free shipping on all orders over $ 500

ABT-751

Cat. No. M1642

All AbMole products are for research use only, cannot be used for human consumption.

ABT-751 Structure
Synonym:

E7010

Size Price Availability Quantity
5mg USD 48  USD48 In stock
10mg USD 70  USD70 In stock
25mg USD 140  USD140 In stock
50mg USD 210  USD210 In stock
100mg USD 335  USD335 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ABT-751 is an orally bioavailable tubulin inhibitor with IC50 of about 1.5 and 3.4 µM in neuroblastoma and non-neuroblastoma cell lines, respectively. ABT-751 had a broad spectrum of antitumor activity in a panel of 30 tumor cell lines in vitro and in xenograft models of human tumors in vivo, including gastric, colorectal, lung, and breast cancer models. ABT-751 showed antitumor activity against a broad spectrum of tumor lines including those resistant to conventional chemotherapies. A single dose of ABT-751 (30 mg/kg, intravenously) induced a rapid, transient reduction in tumor perfusion. After 1 h, tumor perfusion decreased by 57% before recovering to near pretreatment levels within 6 h. In contrast, ABT-751 produced little change in muscle perfusion at either time point. ABT-751, at concentrations corresponding to plasma levels achieved in vivo, caused endothelial cell retraction and significant loss of microtubules within 1 h.

Chemical Information
Molecular Weight 371.41
Formula C18H17N3O4S
CAS Number 141430-65-1
Solubility (25°C) DMSO ≥72 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Gaynon et al. J Pediatr Hematol Oncol. ABT-751 in Relapsed Childhood Acute Lymphoblastic Leukemia.

[2] Silver et al. J Vet Intern Med. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.

[3] Rudin et al. J Clin Oncol. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.

[4] Fox et al. Cancer Chemother Pharmacol. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.

[5] Meany et al. Pediatr Blood Cancer. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.

Related Microtubule Products
CCB02

CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity.

Lisavanbulin

Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862).

20-O-Demethyl-AP3 

20-O-Demethyl-AP3 is a minor metabolite of Ansamitocin P-3.

Lisavanbulin dihydrochloride

Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862).

Paclitaxel-d5

Paclitaxel-d5

  Catalog
Abmole Inhibitor Catalog




Keywords: ABT-751, E7010 supplier, Microtubule, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.